ClinicalTrials.gg

Program

KH815

A development code. Also written as “KH815 for injection”.

Its studies are led by Chengdu Kanghong Pharmaceutical Group.

Furthest: phase 1, since Mar 6, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chengdu Kanghong Pharmaceutical Group11 open or runningphase 1since Mar 6, 2025Mar 6, 2025Jun 30, 2027phase 1 · NCT06885645

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2025First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06885645 · 30 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT06885645

TargetBeta

TACSTD2 →read by rule
“KH815 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting TROP2 antigens.”study text, by rule · the study

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
sacituzumab tirumotecanMerckphase 350
datopotamab deruxtecanruleAstraZenecaphase 328
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06885645Advanced Solid Tumors1Not yet recruitingJun 30, 202730

How it is read

Names in the registry

  • “KH815 for injection”, 1 entry

Codes read as this program: KH815.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.